Adaptin Bio (APTN) Liabilities and Shareholders Equity (2022 - 2026)

Adaptin Bio has reported Liabilities and Shareholders Equity for 5 years, with the latest figure at $706117.0 in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 75.26% year-over-year to $706117.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (up 28.23% YoY) and the FY2025 annual result came in at $619159.0, up 158.61% from the prior year.
• Liabilities and Shareholders Equity improved to $706117.0 in Q1 2026 per APTN's latest filing, from $619159.0 in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $2.9 million in Q1 2025 and troughed at $322.0 in Q2 2024.
• A 5-year average of $588590.7 and a median of $119957.5 in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity jumped 750953.68% in 2025, then slumped 75.26% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $500.0 in 2022, then dropped by 24.0% to $380.0 in 2023, then jumped by 62903.95% to $239415.0 in 2024, then surged by 158.61% to $619159.0 in 2025, then increased by 14.04% to $706117.0 in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $706117.0, $619159.0, and $979474.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.